Gedeptin is under clinical development by GeoVax Labs and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gedeptin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gedeptin overview

Gedeptin (Ad/PNP-F-araAMP) is under development for the treatment of oropharyngeal cancer, nasopharyngeal, salivary gland cancer and head and neck cancer. Ad/PNP is administered intratumorally with co-administration of fludarabine phosphate intravenously. Adenovirus/PNP is an adenovirus loaded with E. coli purine nucleoside phosphorylase (E. coli PNP). The drug candidate is developed based on PNP Technology.

GeoVax Labs overview

GeoVax Labs (GeoVax) is a biotechnology company that develops immunotherapies and vaccines against cancers and various infectious diseases. GeoVax develops vaccines using its novel patented Modified Vaccinia Ankara-Virus like Particle (MVA-VLP) vector vaccine platform focused on therapy areas such as infectious diseases like HIV, Lassa fever, Ebola, Zika virus, malaria, Hepatitis B, coronavirus, and cancers related to solid tumors and HPV-associated head and neck cancer. It has partnerships for preclinical and clinical testing with various government, academic and corporate entities, including the Centers for Disease Control and Prevention (CDC), Leidos Inc, Scripps Research Institute, and Emory University. GeoVax is headquartered in Smyrna, Georgia, the US.

For a complete picture of Gedeptin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.